Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 4, 2012, Pages 537-545

  Ibacache, Mauricio ^a,b   Sanchez, Gina ^b,c   Pedrozo, Zully ^b   Galvez, Felipe ^b,c   Humeres, Claudio ^b,c   Echevarria, Ghislaine ^a   Duaso, Juan ^b,c   Hassi, Mario ^b,c   Garcia, Lorena ^b   Díaz Araya, Guillermo ^b   Lavandero, Sergio ^b,c,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alpha2 adrenergic receptor; Anesthesia; Dexmedetomidine; Myocardial infarction; Myocardial ischemia

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA 2 ADRENERGIC RECEPTOR; DEXMEDETOMIDINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE; PROTEIN KINASE B; YOHIMBINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; EX VIVO STUDY; HEART; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY;

ANIMALS; DEXMEDETOMIDINE; MALE; MYOCARDIAL ISCHEMIA; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY;

RATTUS;

EID: 84856285460     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.12.013     Document Type: Article

References (38)

1. Lee T., Marcantonio E., Mangione C., Thomas E., Polanczyk C., Cook E., Sugarbaker D., Donaldson M., Robert Poss R., Ho K., Ludwig L., Pedan A., Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999, 100:1043-1049.
2. Poldermans D., Hoeks S., Feringa H. Pre-operative risk assessment and risk reduction before surgery. J. Am. Coll. Cardiol. 2008, 51:1913-1924.
3. London M. Beta blockers and alpha2 agonists for cardioprotection. Best Pract. Res. Clin. Anaesthesiol. 2008, 22:95-110.
4. Fleisher L., Beckman J., Brown K., Hugh Calkins H., Chaikof E., Fleischmann K., Freeman W., Froehlich J., Kasper E., Kersten J., Riegel B., Robb J. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2007, 116:e418-e499.
5. Gross E., Gross G. Ligand triggers of classical preconditioning and postconditioning. Cardiovasc. Res. 2006, 70:212-221.
6. Hausenloy D., Yellon D. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail. Rev. 2007, 12:217-234.
7. Fryer R., Pratt P., Hsu A., Gross G. Differential activation of extracellular signal-regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J. Pharmacol. Exp. Ther. 2001, 296:642-649.
8. Hausenloy D., Tsang A., Mocanu M., Yellon D. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. 2005, 288:H971-H976.
9. Wijeysundera D., Bender J., Beattie W. Alpha-2 adrenergic agonists for the prevention of cardiaccomplications among patients undergoing surgery. Cochrane Database Syst. Rev. 2009, 4:CD004126.
10. Biccard B., Goga S., de Beurs J. Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials. Anaesthesia 2008, 63:4-14.
11. Roekaerts P., Prinzen F., De Lange S. Beneficial effects of dexmedetomidine on ischaemic myocardium of anaesthetized dogs. Br. J. Anaesth. 1996, 77:427-429.
12. Willigers H., Prinzen F., Roekaerts P., De Lange S., Durieux M. Dexmedetomidine decreases perioperative myocardial lactate release in dogs. Anesth. Analg. 2003, 96:657-664.
13. Okada H., Kurita T., Mochizuki T., Morita K., Sato S. The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts. Resuscitation 2007, 74:538-545.
14. Collins T. ImageJ for microscopy. Biotechniques 2007, 43:25-30.
15. Oliveri C., Ocaranza M.P., Campos X., Lavandero S., Jalil J. Angiotensin I-converting enzyme modulates neutral endopeptidase activity in the rat. Hypertension 2001, 38:650-654.
16. Bhana N., Goa K., McClellan K. Dexmedetomidine. Drugs 2000, 59:263-268.
17. Buffin-Meyer B., Crassous P., Delage C., Denis C., Schaak S., Paris H. EGF receptor transactivation and PI3-kinase mediate stimulation of ERK by α2A-adrenoreceptor in intestinal epithelial cells: a role in wound healing. Eur. J. Pharmacol. 2007, 574:85-93.
18. El-Assal O., Besner G. HB-EGF enhances restitution after intestinal ischemia/reperfusion via PI3K/Akt and MEK/ERK1/2 activation. Gastroenterology 2005, 129:609-625.
19. Roberts R. α2-adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein: role of phosphatidylinositol 3-kinase and EGF receptor transactivation. Br. J. Pharmacol. 2003, 138:107-116.
20. Wheeler L., WoldeMussie E., Lai R. Role of alpha-2 agonists in neuroprotection. Surv. Ophthalmol. 2003, 48:S47-S51.
21. Karkoulias G., Mastrogianni O., Lymperopoulos A., Paris H., Flordellis C. α2-adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase activation and subtype-specific transactivation of EGFR. Cell. Signal. 2006, 18:729-739.
22. Cheng K., Zimniak P., Raufman J. Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells. Cancer Res. 2003, 63:6744-6750.
23. Daub H., Wallasch C., Lankenau A., Herrlich A., Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 1997, 16:7032-7044.
24. Hausenloy D., Yellon D. Preconditioning and postconditioning: united at reperfusion. Pharmacol. Ther. 2007, 116:173-191.
25. Hausenloy D., Mocanu M., Yellon D. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc. Res. 2004, 63:305-312.
26. Snapir A., Posti J., Kentala E., Koskenvuo J., Sundell J., Tuunanen H., Hakala K., Scheinin H., Knuuti J., Scheinin M. Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology 2006, 105:902-910.
27. Hsu Xylazine-induced depression and its antagonism by alpha adrenergic blocking agents. J. Pharmacol. Exp. Ther. 1981, 218:188-192.
28. Eser O., Fidan H., Sahin O., Cosar M., Yaman M., Mollaoglu H., Songur A., Buyukbas S. The influence of dexmedetomidine on ischemic rat hippocampus. Brain Res. 2008, 1218:250-256.
29. Bylund D. Subtypes of alpha1- and alpha2-adrenergic receptors. FASEB J. 1992, 6:832-839.
30. Berkowitz D., Price D., Bello E., Page S., Schwinn D. Localization of messenger RNA for three distinct alpha 2-adrenergic receptor subtypes in human tissues. Evidence for species heterogeneity and implications for human pharmacology. Anesthesiology 1994, 81:1235-1244.
31. El-Ayoubi R., Menaouar A., Gutkowska J., Mukaddam-Daher S. Imidazoline receptors but not alpha2-adrenoceptors are regulated in spontaneously hypertensive rat heart by chronic moxonidine treatment. J. Pharmacol. Exp. Ther. 2004, 310:446-451.
32. 2c2 mRNA in multiple tissues. Mol. Pharmacol. 1993, 44:70-75.
33. Lorenz W., Lomasney J., Collins S., Regan J., Caron M., Lefkowitz R. Expression of three α2-adrenergic receptor subtypes in rat tissues: implications for α2 receptor classification. Mol. Pharmacol. 1990, 38:599-603.
34. Handy D., Flordellis C., Bogdanova N., Bresnahan M., Gavras H. Diverse tissue expression of rat alpha 2-adrenergic receptor genes. Hypertension 1993, 21:861-865.
35. Whelan R., Kaplinskiy V., Kitsis R. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu. Rev. Physiol. 2010, 72:19-44.
36. Fliss H., Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ. Res. 1996, 79:949-956.
37. Chiong M., Wang Z.V., Pedrozo Z., Cao D.J., Troncoso R., Ibacache M., Criollo A., Nemchenko A., Hill J.A., Lavandero S. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis. 2011, 2e:244.
38. Joshi M., Ferguson T.B., Johnson F., Johnson R., Parthasarathy S., Lancaster J. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9982-9987.